Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study (Q45711971)

15 December 2017

Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study (English)

1 reference

15 December 2017

0 references

1 reference

11

1 reference

15 December 2017

Daria Lucia Trabattoni

object named as

Daria Trabattoni

9

0 references

author name string

Carlo L Cazzullo

1

1 reference

15 December 2017

Emilio Sacchetti

2

1 reference

15 December 2017

Alessandro Galluzzo

3

1 reference

15 December 2017

Adelaide Panariello

4

1 reference

15 December 2017

Andrea Adorni

5

1 reference

15 December 2017

Marco Pegoraro

6

1 reference

15 December 2017

Simona Bosis

7

1 reference

15 December 2017

Fulvia Colombo

8

1 reference

15 December 2017

Arianna Zagliani

10

1 reference

15 December 2017

1 January 2002

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

15 December 2017

1 reference

15 December 2017

26

1 reference

15 December 2017

1

1 reference

15 December 2017

33-39

1 reference

Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro.

15 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Clinical and laboratory evidence of autoimmunity in acute schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

IL-2 responsiveness of lectin-induced lymphoblasts: soluble IL-2 receptor release and differential in vitro effects of immunosuppressants

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Decreased interleukin-2 production in Korean schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

A new five factor model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Immunoendocrine aspects of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

In vivo immunomodulatory effects of clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Reduced lymphocyte response to PHA and OKT3 in drug-free and neuroleptic-treated chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Effects of clozapine on plasma cytokine and soluble cytokine receptor levels

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Elevated levels of soluble interleukin 2 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Immunological dysfunction in schizophrenia: a systematic approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

Immunologic and Coagulation Disorders in Chlorpromazine-Treated Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900221-4

7 January 2021

10.1016/S0278-5846(01)00221-4

Identifiers

DOI

1 reference

15 December 2017

1 reference